157 related articles for article (PubMed ID: 36095125)
41. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
42. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
43. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
[TBL] [Abstract][Full Text] [Related]
44. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts.
Patnaik MM; Hanson CA; Sulai NH; Hodnefield JM; Knudson RA; Ketterling RP; Lasho TL; Tefferi A
Blood; 2012 Jun; 119(24):5674-7. PubMed ID: 22538853
[TBL] [Abstract][Full Text] [Related]
45. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
46. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
47. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract][Full Text] [Related]
48. Myelodysplastic syndromes and the role of iron overload.
Harvey RD
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
[TBL] [Abstract][Full Text] [Related]
49. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
50. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
51. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
52. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
53. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
Merkel DG; Nagler A
Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
55. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
[TBL] [Abstract][Full Text] [Related]
56. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
57. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.
Giagounidis A; Leto di Priolo S; Ille S; Fenaux P
Ann Hematol; 2011 Jun; 90(6):667-73. PubMed ID: 21327403
[TBL] [Abstract][Full Text] [Related]
58. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China.
Wang Y; Huang L; Hua Y; Liu H; Jiang H; Wang H; Zhang W; Fu R; Shao Z
Hematology; 2021 Dec; 26(1):874-880. PubMed ID: 34753406
[TBL] [Abstract][Full Text] [Related]
59. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.
Steensma DP
Curr Hematol Malig Rep; 2011 Jun; 6(2):136-44. PubMed ID: 21373838
[TBL] [Abstract][Full Text] [Related]
60. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
